Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
The compliance notice resolves the minimum bid price matter, but does not cover Nasdaq’s other continued listing requirements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medicus Pharma (Nasdaq: MDCX) has regained compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The company received written confirmation from Nasdaq’s Listing Qualifications Department on October 23, 2026. Nasdaq determined that its common shares had maintained a closing bid price of at least $1.00 for ten consecutive business days, from October 12 through October 23, 2026, satisfying Listing Rule 5550(a)(2). Nasdaq has closed the minimum bid price matter.
The notice relates only to the minimum bid price requirement; Medicus remains subject to Nasdaq’s other continued listing requirements. Additional details are available in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNasdaq minimum bid price compliance regained; Nasdaq closed the matter after ten consecutive business days at or above $1.00.
Negative
- None.
Key Figures
- Minimum bid price threshold
- $1.00 per share
- Nasdaq continued-listing requirement
- Consecutive qualifying business days
- 10 consecutive business days
- Closing bids were at least $1.00 from October 12 through October 23, 2026
Key Terms
form 8-k regulatory
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance
PHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it received written notice on October 23, 2026 (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the
The Compliance Notice relates specifically to the minimum bid price requirement. The Company remains subject to Nasdaq’s other continued listing requirements, and there can be no assurance that it will maintain compliance with the minimum bid price requirement or other continued listing requirements in the future.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.
The Company’s current therapeutic assets are:
CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.
SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.
Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.
Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.
Cautionary Notice on Forward-Looking Statements
[raza- updated below to conform more closely with Medicus standard for news releases]
Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements concerning the continued listing of the Company’s securities on Nasdaq and the Company’s ability to maintain compliance with the minimum bid price requirement and Nasdaq’s other continued listing requirements.
All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. In addition, forward-looking statements are typically identified by words such as “plan,” “believe,” “goal,” “target,” “aim,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, although the absence of these words or expressions does not mean that a statement is not forward-looking.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2025, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Medicus Pharma regain Nasdaq minimum bid price compliance?
Medicus Pharma’s common shares maintained a closing bid price of at least $1.00 for ten consecutive business days, from October 12 through October 23, 2026. Nasdaq confirmed compliance with Listing Rule 5550(a)(2) in a written notice received on October 23, 2026.